Optalert developed the world’s preeminent algorithm for objectively quantifying deterioration in cognitive function – the Johns Drowsiness Scale™ (JDS). It remains the only scientifically proven, objective measure of drowsiness and impairment. The firm holds multiple patents on its proprietary biomarker that Harvard Medical School has deemed “commensurate with gold standard laboratory measures”.
The company also discovered the first non-invasive method to screen for obstructive sleep apnoea (OSA) while the test subject is awake. It is also making progress in early screening of Alzheimer’s, Parkinson’s, and other neurodegenerative conditions. Detection of these far in advance of visible symptoms will add years or even decades of well-being to millions of people in the future.
All of Optalert’s technologies are based on blepharometry. This term was introduced by founder Dr. Murray Johns to define the unique study of measuring eyelid movement, captured through a sensor or camera. Eyelid movements require precise coordination between two areas of the brain. They are a window into a person’s underlying neurological state.
Optalert is active in a range of sectors with a diverse suite of products. In the mining and transport sector it offers a comprehensive fleet management solution to monitor and manage risk from drowsiness. It licenses its drowsiness algorithm to automakers for integration in their driver monitoring systems. It is also in the process of commercialising its breakthroughs in early screening of neurological and health conditions.
Optalert’s mission is to give everyone access to a comprehensive set of health information that is low-cost, frequent, and non-invasive. This helps millions of people live longer, healthier lives – all in the blink of an eye.
Renowned as experts in drowsiness and impairment detection, Optalert is now exploring new pathways in the automotive industry, pharmaceutical drug trials and neurological research.
Sign up today to keep up to date with the latest news from Optalert.